Renal amyloidosis epidemiology and demographics

Jump to navigation Jump to search

Renal amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Renal amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography or Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Template:Renal amyloidosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Renal amyloidosis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Renal amyloidosis epidemiology and demographics

CDC on Renal amyloidosis epidemiology and demographics

Renal amyloidosis epidemiology and demographics in the news

Blogs on Renal amyloidosis epidemiology and demographics

Directions to Hospitals Treating Cystic fibrosis

Risk calculators and risk factors for Renal amyloidosis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2] Omer Kamal, M.D. [2]

Overview

The incidence is 9.7 to 14.0 cases per million person-years. The prevalence of AL amyloidosis was 40.5 in 2015, an annual percentage change (APC) of 12%. In renal amyloidosis, is usually first diagnosed in average age of 65 years and it is uncommon before age of 40.

Epidemiology and Demographics

Incidence

The incidence is 9.7 to 14.0 cases per million person-years.[1]

Prevalence

The prevalence of AL amyloidosis was 40.5 in 2015, an annual percentage change (APC) of 12%. [1]

Mortality rate

  • AL has higher mortality than AA type[2]

Age

  • The incidence of renal amyloidosis increases with age; the median age at diagnosis is 65 years.[3][4]

Race

  • There is no racial predilection to renal amyloidosis.

Gender

  • Males are are more commonly affected by renal amyloidosis.
  • The male to female ratio is approximately 2 to 1.[3]

Region

  • ALECT2 is more frequent in the United States area.[5]
  • AFib cases are most reported in Europe countries.

References

  1. 1.0 1.1 Quock TP, Yan T, Chang E, Guthrie S, Broder MS (May 2018). "Epidemiology of AL amyloidosis: a real-world study using US claims data". Blood Adv. 2 (10): 1046–1053. doi:10.1182/bloodadvances.2018016402. PMC 5965052. PMID 29748430.
  2. Bollée G, Guery B, Joly D, Snanoudj R, Terrier B, Allouache M, Mercadal L, Peraldi MN, Viron B, Fumeron C, Elie C, Fakhouri F (March 2008). "Presentation and outcome of patients with systemic amyloidosis undergoing dialysis". Clin J Am Soc Nephrol. 3 (2): 375–81. doi:10.2215/CJN.02470607. PMC 2390937. PMID 18184882.
  3. 3.0 3.1 Khalighi MA, Dean Wallace W, Palma-Diaz MF (April 2014). "Amyloid nephropathy". Clin Kidney J. 7 (2): 97–106. doi:10.1093/ckj/sfu021. PMC 4377792. PMID 25852856.
  4. Hajra A, Bandyopadhyay D (2016). "An interesting case of renal amyloidosis". Indian J Nephrol. 26 (6): 467–469. doi:10.4103/0971-4065.177143. PMC 5131391. PMID 27942184.
  5. Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, Herrera Hernandez L, Vrana JA, Theis JD, Quint PS, Dogan A, Nasr SH (September 2013). "Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases". Clin J Am Soc Nephrol. 8 (9): 1515–23. doi:10.2215/CJN.10491012. PMC 3805078. PMID 23704299.

Template:WH Template:WS